In recent years, the scientific and medical community's relentless pursuit of reliable biomarkers for early disease detection and management has led to the discovery of an outstanding candidate, c-MET.
What is c-MET?
c-MET, or hepatocyte growth factor receptor (HGFR), is a receptor tyrosine kinase encoded by the MET gene. This protein is essential for many cellular processes and plays a central role in regulating cell proliferation, migration and tissue repair. Under normal conditions, c-MET is activated in response to its primary ligand, hepatocyte growth factor (HGF). This binding initiates intracellular signaling cascades that influence cell survival, differentiation, and tissue regeneration.
c-MET as a Biomarker
The role of c-MET as a biomarker is most prominent in the field of cancer. c-MET overexpression is a recurring theme in various cancer types, including lung, breast, liver, and gastric cancers. Elevated c-MET levels are often associated with more aggressive tumor behavior, increased metastasis, and poorer prognosis.
In addition to cancer, the effects of c-MET extend to neurological disorders. The c-MET pathway is associated with brain development and function. Researchers have linked abnormal c-MET signaling to conditions such as autism, Alzheimer's disease and schizophrenia. These links, although not fully elucidated, suggest the potential of c-MET as a biomarker for neurological disorders.
The impact of c-MET on cardiovascular disease is increasingly recognized. It is involved in the regulation of cardiac function and angiogenesis, the formation of new blood vessels. Dysregulation of c-MET in cardiovascular tissue may lead to heart disease, including heart failure. By detecting abnormal c-MET levels, we can predict and assess cardiac conditions, potentially making early intervention possible.
Detection Methods for c-MET
- Immunohistochemistry (IHC)
Immunohistochemistry is a basic method for assessing c-MET in tissue samples. Using specific antibodies, IHC enables visualization of c-MET expression in fixed tissue sections. The extent and distribution of staining provide valuable insights into c-MET expression, making it an indispensable tool in studying cancer biopsies and other tissue-based analyses.
- Enzyme-Linked Immunosorbent Assay (ELISA)
ELISA is a highly sensitive and specific method for quantifying c-MET levels in body fluids, including blood and urine. ELISA enables non-invasive assessment through the interaction between c-MET and antibodies. This technology is critical for monitoring treatment response and large-scale screening.
- Polymerase Chain Reaction (PCR)
Molecular biology techniques such as PCR, especially quantitative PCR (qPCR), have enabled the quantification of c-MET mRNA. qPCR allows for quantitative assessment of c-MET by measuring gene expression levels in various samples. It is particularly valuable for studying changes in gene expression associated with disease development.
- Next Generation Sequencing (NGS)
NGS technology has revolutionized the identification of genetic alterations, including mutations and copy number variations in the MET gene. These genetic changes can profoundly affect c-MET expression and function. NGS can help identify c-MET-related genetic abnormalities, particularly in cancer research.
The emergence of c-MET as a biomarker offers prospects for advancing personalized medicine. By assessing c-MET status and activity, clinicians can tailor treatment strategies to individual patients. The journey of c-MET from a fundamental biological molecule to a critical biomarker emphasizes the dynamic nature of medical research and its ability to revolutionize disease management.
Related Services
